About this trial
Patients treated for breast cancer frequently complain of sleep disturbances, about 40% of them. Of the sleep disturbances experienced by patients, insomnia is the most common complaint. The prevalence of insomnia complaints is higher in breast cancer patients compared to other types of cancer, and is also higher than in the general population (between 20% and 70% in breast cancer patients vs 30% in the general population). A recent study indicates that sleep complaints concern 25% of patients even before diagnosis, and 46% (including 18% complaining of insomnia) at the time of diagnosis, showing the negative impact of the announcement of the pathology on the subjective quality of sleep, and particularly on symptoms suggestive of insomnia. However, objective information on a modification of sleep patterns in breast cancer remains scarce and does not allow us to conclude. In particular, previous studies have focused only on the effects of chemotherapy and have not always included a control group, limiting the significance of their results. The links with cognitive and psychopathological processes and the underlying mechanisms are not clearly demonstrated in this pathology. Finally, taking into account patients' complaints, it appears necessary to limit sleep disorders in breast cancer in order to improve patients' quality of life using non-medicinal and easy-to-implement approaches.
Eligibility criteria
Qualifiers
Patients aged 39 to 69 years
Patient with operated localized breast cancer who may or may not be starting adjuvant chemotherapy
Patient with education level 3 "end of primary education"
Patient with a good command of the French language
Disqualifiers
Patient with metastatic cancer
Patient with a primary cancer other than breast cancer
Patient with a history of neurological damage
Patient with treated sleep apnea
Trial design
Treatments tested in this trial
- Functional Magnetic Resonance Imaging at rest and in activation with attentional task
Treatment groups
Sponsors and collaborators
Centre Francois Baclesse
Lead sponsor
UMR_S 1077 Inserm-EPHE-Normandie Université
Collaborator